EcoR1 Capital PRLD Position
Exited4-Fund ConvergenceEcoR1 Capital exited their position in Prelude Therapeutics Inc. (PRLD) in Q4 2023, after holding the stock for 3 quarters.
The position was first reported in Q2 2023 and has been tracked across 3 quarterly 13F filings.
PRLD is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 19.0% of float with 6.5 days to cover, indicating significant bearish positioning against the stock.
About Prelude Therapeutics Inc.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Full company profile →Short Interest
19.0%
6.5 days to cover
EcoR1 Capital PRLD Position History
Frequently Asked Questions
Does EcoR1 Capital own PRLD?
No. EcoR1 Capital exited their position in Prelude Therapeutics Inc. (PRLD) in Q4 2023. They previously held the stock for 3 quarters.
How many hedge funds own PRLD?
4 specialist biotech hedge funds currently hold PRLD, including Baker Bros. Advisors, OrbiMed Advisors, Deerfield Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy PRLD?
EcoR1 Capital's position in PRLD was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's PRLD position increasing or decreasing?
EcoR1 Capital completely exited their PRLD position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PRLDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →